Telephone
61.3.9826.0399
Address
Level 4 Suite 0403 650 Chapel Street South Yarra, Victoria (VIC) 3141
Description
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984, and is headquartered in South Yarra, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.31 - 0.97
Trade Value (12mth)
AU$67,296.00
1 week
20.24%
1 month
46.38%
YTD
-40.81%
1 year
-44.2%
All time high
3.91208
EPS 3 yr Growth
611.700%
EBITDA Margin
%
Operating Cashflow
-$179m
Free Cash Flow Return
-586.90%
ROIC
-693.50%
Interest Coverage
-11.20
Quick Ratio
5.20
Shares on Issue (Fully Dilluted)
496m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.22
Date | Announcements |
---|---|
31 October 23 |
Opthea to present at Eyecelerator at AAO
×
Opthea to present at Eyecelerator at AAO |
31 March 22 |
Change in substantial holding
×
Change in substantial holding |
31 January 23 |
Opthea to Present at Sequire Biotechnology Conference
×
Opthea to Present at Sequire Biotechnology Conference |
31 January 22 |
Becoming a substantial holder
×
Becoming a substantial holder |
31 January 08 |
Circadian Technologies - Corporate Presentation
×
Circadian Technologies - Corporate Presentation |
31 January 08 |
Circadian Technologies - Corporate Presentation (amended)
×
Circadian Technologies - Corporate Presentation (amended) |
31 August 23 |
Opthea Retail Entitlement Offer Opens
×
Opthea Retail Entitlement Offer Opens |
31 August 23 |
Preliminary Final Report
×
Preliminary Final Report |
30 September 22 |
Application for quotation of securities - OPT
×
Application for quotation of securities - OPT |
30 September 15 |
Circadian Technologies Limited - Annual Report 2015 (CIR-AU)
×
Circadian Technologies Limited - Annual Report 2015 (CIR-AU) |
30 September 14 |
Circadian Technologies Limited - Annual Report 2014 (CIR-AU)
×
Circadian Technologies Limited - Annual Report 2014 (CIR-AU) |
30 October 15 |
Circadian Technologies Limited - Notice of Annual General Meeting and Proxy Form (CIR-AU)
×
Circadian Technologies Limited - Notice of Annual General Meeting and Proxy Form (CIR-AU) |
30 November 23 |
2023 AGM Chairmans Address
×
2023 AGM Chairmans Address |
30 November 23 |
Results of Meeting
×
Results of Meeting |
30 November 22 |
Appendix 2A
×
Appendix 2A |
30 November 22 |
Cleansing Notice
×
Cleansing Notice |
30 November 15 |
Circadian Technologies Limited - Chairman's address to the Annual General Meeting (CIR-AU)
×
Circadian Technologies Limited - Chairman's address to the Annual General Meeting (CIR-AU) |
30 November 15 |
Circadian Technologies Limited - CEO Presentation for the Annual General Meeting (CIR-AU)
×
Circadian Technologies Limited - CEO Presentation for the Annual General Meeting (CIR-AU) |
30 November 15 |
Circadian Technologies Limited - Results of the Annual General Meeting (CIR-AU)
×
Circadian Technologies Limited - Results of the Annual General Meeting (CIR-AU) |
30 March 22 |
Change in substantial holding
×
Change in substantial holding |
30 August 22 |
Opthea Appendix 4E and Annual Report 2022
×
Opthea Appendix 4E and Annual Report 2022 |
30 August 22 |
Opthea reports Fiscal Year 2022 Results and Highlights
×
Opthea reports Fiscal Year 2022 Results and Highlights |
30 August 22 |
Opthea Appendix 4G Corporate Governance Statement 2022
×
Opthea Appendix 4G Corporate Governance Statement 2022 |
30 August 21 |
Opthea Appendix 4E and Annual Report
×
Opthea Appendix 4E and Annual Report |
30 August 17 |
Opthea Appendix 4E and Annual Report 2017
×
Opthea Appendix 4E and Annual Report 2017 |
30 April 07 |
To present at US Investor Forums
×
To present at US Investor Forums |
29 October 18 |
Notice of Annual General Meeting and Proxy Form
×
Notice of Annual General Meeting and Proxy Form |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.